MIAMI, Dec. 20, 2019 — Longeveron LLC, a leading developer of adult stem cell technologies for chronic, aging-related and life-threatening conditions, announced today that it has completed enrollment in its Phase 1 Alzheimer’s disease trial. This randomized, double-blind, placebo-controlled study is designed to evaluate the safety and efficacy of LMSCs in patients with mild Alzheimer’s disease (AD). [Read more…]
BMS Pays Evotec $6M as Companies Expand iPSC Collaboration
Adding Cell Types Supports Drug Discovery of Disease-Modifying Therapies for Neurodegenerative Diseases and Triggues U.S. $6 M Payment to Evotec
Hamburg, Germany, January 7, 2020 – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that the Company received a US$ 6 m payment from Bristol-Myers Squibb Company (NYSE:BMY) following the decision to expand the collaboration to include additional cell lines.
Evotec and Celgene, which is now a Bristol-Myers Squibb company, initiated the collaboration in December 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases. Currently approved drugs only offer short-term management of patients’ symptoms and there is a huge unmet medical need for therapies that slow down or reverse disease progression in the field of neurodegenerative diseases.
This collaboration pursues an innovative approach to the discovery and development of novel medicines by leveraging several of Evotec’s unique technology platforms in conjunction with the human iPSC based platform, which is one of the largest and most sophisticated platforms in the industry. The iPSC partnership between Bristol-Myers Squibb and Evotec has already been expanded with additional cell lines several times. [Read more…]
International Perinatal Stem Cell Society to Host Two Scientific Conferences in 2020
The International Perinatal Stem Cell Society is a non-profit organization founded on the principle that stem cells from perinatal tissues contain enormous, untapped potential to treat many diseases and disorders worldwide.
For many years, the Perinatal Stem Cell Society has been hosting an annual conference featuring the world’s leading perinatal stem cell researchers, specializing in Amnion, Amniotic Fluid, Cord Blood for Regenerative Medicine, Cord Tissue, and the Placenta. Its scientific programs cover all aspects of the perinatal stem cell field, with opportunities to learn from leading clinicians utilizing cellular therapies within their practices.
Below, Kyle Cetrulo, President of the International Perinatal Stem Cell Society, explains the future of perinatal stem cell science and the role that the Society’s 2020 Scientific Conferences will play in advancing this mission. [Read more…]
Lineage Cell Therapeutics and AgeX Therapeutics Announce Issuance of U.S. Patent for Method of Generating iPS Cells
Lineage Cell and AgeX get issued U.S. Patent that Precedes the first scientific publication of Shinya Yamanaka.
CARLSBAD, Calif., Dec 10, 2019 — Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX) and AgeX Therapeutics, Inc. (NYSE American: AGE), announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,501,723, entitled “Methods of Reprogramming Animal Somatic Cells” covering what is commonly designated “induced Pluripotent Stem (iPS) cells.” The issued claims include methods to manufacture pluripotent cells capable of becoming any cell in the body.
The patent has an early priority date, having been filed before the first scientific publication of Shinya Yamanaka, for which he won the Nobel Prize for Physiology or Medicine in 2012. [Read more…]
The Countdown is On for Phacilitate Leaders World, part of Advanced Therapies Week, and the World Stem Cell Summit 2020
Each year, the BioInformant team enjoys participating in Phacilitate Leaders World, now part of Advanced Therapies Week, and the World Stem Cell Summit, which is co-hosted with the event.
This year’s conference is being held this year from Jan 21-24, 2020, in Miami, Florida, and will be the single largest networking event of the year, bringing together the entire ecosystem of the advanced therapies industry from across the globe.
If you can only attend one conference this year, I’d recommend this one because it attracts several thousand attendees, 350+ organizations, and 200+ speakers.
It’s also two events in one, because Phacilitate Leaders World (part of Advanced Therapies Week) is co-hosted with the World Stem Cell Summit, making it an opportunity to connect with new and existing clients and partners worldwide.
If your team is thinking to attend or sponsor, we received a code (“BIOINFORMANT“) for our community to get 10% off both delegate passes and event sponsorship.
Early bird registration discounts end on November 22, 2019, so if you act soon, you’ll get the best possible deal.
Will I see you there?
If you’re not able to make it, what other events are on your schedule for 2020? It’d be great to meet in person.
Cade
- « Previous Page
- 1
- …
- 100
- 101
- 102
- 103
- 104
- …
- 201
- Next Page »